{
  "DOI": "10.1038/s41431-022-01260-1",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-022-01260-1",
  "alternative-id": [
    "1260"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "14 April 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "21 November 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "29 November 2022"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "5 January 2023"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "This work has received support from Utragenyx for medical writing and figure creation. CVS declares that she has in the past received funding from Ultragenyx for conference presentations and honoraria for participating in their Scientific Working Group. CVS is also Scientific Advisor (an unpaid role) for the ERNDIM (European Research Network for evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of Metabolism). AF declares that his institution has received funding from Amicus and Sanofi-Genzyme. AF has also received honoraria for participation on advisory boards from Amicus. JV declares that he has in the past received research funding from Ultragenyx and Reneo Pharmaceuticals. JV has also received payment or honoraria from CheckRare CME, Excel CEM, PTCE-PER CME, Med-IQ CME and Horizon Pharmaceuticals CME. JV plays are leadership from in SIMD NAMA and holds stocks in American Gene Therapies. CAB declares that she has received honoraria in the past for participating in scientific working groups for Utragenyx and Alnylam, and is unpaid board member of ANPGM, the French Association of Genetic Molecular Practitioners. NG declares that her institution has been the recipient of grants for clinical trials from Sanofi-Genzyme, Takeda and Chiesi. NG has received support for attending scientific meetings from Ultragenyx, Sanofi-Genzyme and Chiesi, as well as honoraria for participation on data safety monitoring and advisory boards from Ultragenyx, Sanofi-Genzyme, Chiesi and Biomarin."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0001-8477-3120",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Vianey-Saban",
      "given": "Christine",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Fouilhoux",
      "given": "Alain",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Vockley",
      "given": "Jerry",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-3828-6847",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Acquaviva-Bourdain",
      "given": "Cécile",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Guffon",
      "given": "Nathalie",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2023,
        1,
        5
      ]
    ],
    "date-time": "2023-01-05T03:20:48Z",
    "timestamp": 1672888848000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        3,
        26
      ]
    ],
    "date-time": "2023-03-26T19:35:02Z",
    "timestamp": 1679859302000
  },
  "funder": [
    {
      "DOI": "10.13039/100013220",
      "doi-asserted-by": "publisher",
      "name": "Ultragenyx Pharmaceutical"
    },
    {
      "name": "This work has received support from Ultragenyx for medical writing and figure creation."
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2023,
        3,
        26
      ]
    ],
    "date-time": "2023-03-26T20:12:50Z",
    "timestamp": 1679861570554
  },
  "is-referenced-by-count": 0,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "3",
  "issued": {
    "date-parts": [
      [
        2023,
        1,
        5
      ]
    ]
  },
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2023,
          3
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            1,
            5
          ]
        ],
        "date-time": "2023-01-05T00:00:00Z",
        "timestamp": 1672876800000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2023,
            1,
            5
          ]
        ],
        "date-time": "2023-01-05T00:00:00Z",
        "timestamp": 1672876800000
      }
    }
  ],
  "link": [
    {
      "URL": "https://www.nature.com/articles/s41431-022-01260-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-022-01260-1",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://www.nature.com/articles/s41431-022-01260-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "265-272",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2023,
        1,
        5
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2023,
        1,
        5
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2023,
        3
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1038/s41436-020-01070-0",
      "author": "D Marsden",
      "doi-asserted-by": "publisher",
      "first-page": "816",
      "journal-title": "Genet Med",
      "key": "1260_CR1",
      "unstructured": "Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23:816–29.",
      "volume": "23",
      "year": "2021"
    },
    {
      "key": "1260_CR2",
      "unstructured": "Spiekerkoetter U, Vockley J. Mitochondrial fatty acid oxidation defects. In: Blau N, Dionisi-Vici C, Ferreira CR, Vianey-Saban C, van Karnebeek CDM editors, Physician’s guide to the diagnosis, treatment and follow-up of inherited disorders. Switzerland: Springer Nature; 2022, pp 929–57."
    },
    {
      "DOI": "10.1097/PEC.0000000000001093",
      "author": "SH Aldubayan",
      "doi-asserted-by": "publisher",
      "first-page": "296",
      "journal-title": "Pediatr Emerg Care",
      "key": "1260_CR3",
      "unstructured": "Aldubayan SH, Rodan LH, Berry GT, Levy HL. Acute illness protocol for fatty acid oxidation and carnitine disorders. Pediatr Emerg Care. 2017;33:296–301.",
      "volume": "33",
      "year": "2017"
    },
    {
      "DOI": "10.1002/jimd.12372",
      "author": "SC Grünert",
      "doi-asserted-by": "publisher",
      "first-page": "893",
      "journal-title": "J Inherit Metab",
      "key": "1260_CR4",
      "unstructured": "Grünert SC, Eckenweiler M, Haas D, Lindner M, Tsiakas K, Santer R, et al. The spectrum of peripheral neuropathy in disorders of the mitochondrial trifunctional protein. J Inherit Metab. 2021;44:893–902.",
      "volume": "44",
      "year": "2021"
    },
    {
      "DOI": "10.1016/j.ymgme.2012.02.015",
      "author": "AL Fletcher",
      "doi-asserted-by": "publisher",
      "first-page": "18",
      "journal-title": "Mol Genet Metab",
      "key": "1260_CR5",
      "unstructured": "Fletcher AL, Pennesi ME, Harding CO, Weleber RG, Gillingham MB. Observations regarding retinopathy in mitochondrial trifunctional protein deficiencies. Mol Genet Metab. 2012;106:18–24.",
      "volume": "106",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.ymgme.2021.02.003",
      "author": "N Guffon",
      "doi-asserted-by": "publisher",
      "first-page": "227",
      "journal-title": "Mol Genet Metab",
      "key": "1260_CR6",
      "unstructured": "Guffon N, Mochel F, Schiff M, De Lonlay P, Douillard C, Vianey-Saban C. Clinical outcomes in a series of 18 patients with long chain fatty acids oxidation disorders treated with triheptanoin for a median duration of 22 months. Mol Genet Metab. 2021;132:227–33.",
      "volume": "132",
      "year": "2021"
    },
    {
      "DOI": "10.3390/ijns7010015",
      "author": "JG Loeber",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "journal-title": "Int J Neonatal Screen",
      "key": "1260_CR7",
      "unstructured": "Loeber JG, Platis D, Zetterstrom RH, Almashanu S, Boemer F, Bonham JR, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen. 2021;7:15–36.",
      "volume": "7",
      "year": "2021"
    },
    {
      "key": "1260_CR8",
      "unstructured": "Matern D. Acylcarnitines. In: Blau N, Dionisi-Vici C, Ferreira CR, Vianey-Saban C, van Karnebeek CDM, editors. Physician’s guide to the diagnosis, treatment and follow-up of inherited disorders. Switzerland: Springer Nature; 2022, pp 65–74."
    },
    {
      "DOI": "10.1016/j.cca.2009.04.026",
      "author": "AF Dessein",
      "doi-asserted-by": "publisher",
      "first-page": "23",
      "journal-title": "Clin Chim Acta",
      "key": "1260_CR9",
      "unstructured": "Dessein AF, Fontaine M, Dobbelaere D, Mention-Mulliez K, Martin-Ponthieu A, Briand G, et al. Deuterated palmitate-driven acylcarnitine formation by whole-blood samples for a rapid diagnostic exploration of mitochondrial fatty acid oxidation disorders. Clin Chim Acta. 2009;406:23–6.",
      "volume": "406",
      "year": "2009"
    },
    {
      "DOI": "10.1007/978-3-030-67727-5_32",
      "doi-asserted-by": "crossref",
      "key": "1260_CR10",
      "unstructured": "Vianey-Saban C, Acquaviva C, Bosch AM. Disorders of riboflavin metabolism. In: Blau N, Dionisi-Vici C, Ferreira CR, Vianey-Saban C, van Karnebeek CDM, editors. Physician’s guide to the diagnosis, treatment and follow-up of inherited disorders. Switzerland: Springer Nature; 2022, pp 548–62."
    }
  ],
  "reference-count": 10,
  "references-count": 10,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-022-01260-1"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Improving diagnosis of mitochondrial fatty-acid oxidation disorders"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "31"
}